Zimmer Biomet Completes Acquisition of Monogram Technologies for Orthopedic Robotics.

Zimmer Biomet has completed the acquisition of Monogram Technologies, an AI-driven orthopedic robotics company. The acquisition adds new, differentiated capabilities to Zimmer Biomet's technology solutions, including the first fully autonomous robotic technology for orthopedic procedures. The transaction creates the broadest and most flexible portfolio of orthopedic robotics and navigation technologies.

Zimmer Biomet (NYSE: ZBH) has completed the acquisition of Monogram Technologies, an AI-driven orthopedic robotics company. The acquisition adds new, differentiated capabilities to Zimmer Biomet's technology solutions, including the first fully autonomous robotic technology for orthopedic procedures. The transaction creates the broadest and most flexible portfolio of orthopedic robotics and navigation technologies.

The acquisition includes Monogram's semi-autonomous total knee arthroplasty system, which received FDA 510(k) clearance in March 2025 and is set for commercialization alongside Zimmer Biomet implants by early 2027. Monogram's fully autonomous orthopedic robotic system is currently in clinical trials, scheduled to begin in July 2025.

The deal will allow Zimmer Biomet to offer both CT-based and imageless robotic options, while also developing one of the first fully autonomous surgical robotic systems. This acquisition strengthens Zimmer Biomet's competitive position against other orthopedic surgical robot developers like Stryker, Smith+Nephew, and Johnson & Johnson.

Under the merger agreement, each outstanding share of Monogram common stock converted into $4.04 in cash plus non-tradeable contingent value rights worth up to $12.37 if development, regulatory, and revenue milestones are met by 2030. Monogram shares stopped trading on Nasdaq before the market opened on Oct. 7 and will be delisted.

The acquisition aligns with Zimmer Biomet's strategic goal to provide surgeons with a broad choice in robotics and navigation across various procedures and care settings. CEO Ivan Tornos stated, "By bringing Monogram into the Zimmer Biomet innovation ecosystem, we have set a bold course to become the first orthopedic company to offer a fully autonomous robotic solution complementing our current robotic and navigation offerings."